Friday, January 25, 2019 11:49:25 AM
I just finished talking with dr NP.
I had a very nice talk with him , but of course he couldn't tell me many details...
TNBC - no patients injected at this point , they finishing preparation of the lab in Wisconsin for a blood test for CTC. It is a complicated process.
They almost done. They expecting patients starting treatment in one or two weeks. Dr NP will put PR when this will happen.
Many doctors from big oncology centers calling and asking to accept their patients , so when it will start it should not be very difficult enrollment.
Dr Pestell studies pointing to a VERY good results ..everyone exited about it ....
Pivotal mono- They having very good talk with FDA and probably dr NP will PR within couple of weeks or so...what will be decided.
He couldn't tell me any details , and I do understand that .
Approval of prognostic prostate cancer test - will be somehow affected by gov shut down, but talks about licensing are on going , and things looking good and will be PR when there is something to PR . ( should not be that long )
BLA maybe affected little by gov shut down but he think not very drastic way.
I asked if they are thinking about check point inhibitors and their side effects , really autoimmune diseases and our Leronlimab maybe helpful to prevent those serious problems.
Dr NP said that yes , they are talking about it , it was also their observation that Leronlimab may prevent or at least minimize those severe sometime side effects of check point inhibitors ,
but for now priority is TNBC and HIV.
But they did make this observation..
And I didnt ask anything about money , sorry , when I start to talk medicine I just dont remember other things.
All together my feeling is that they believe 2019 will be very important
OUR year !!!
I had a very nice talk with him , but of course he couldn't tell me many details...
TNBC - no patients injected at this point , they finishing preparation of the lab in Wisconsin for a blood test for CTC. It is a complicated process.
They almost done. They expecting patients starting treatment in one or two weeks. Dr NP will put PR when this will happen.
Many doctors from big oncology centers calling and asking to accept their patients , so when it will start it should not be very difficult enrollment.
Dr Pestell studies pointing to a VERY good results ..everyone exited about it ....
Pivotal mono- They having very good talk with FDA and probably dr NP will PR within couple of weeks or so...what will be decided.
He couldn't tell me any details , and I do understand that .
Approval of prognostic prostate cancer test - will be somehow affected by gov shut down, but talks about licensing are on going , and things looking good and will be PR when there is something to PR . ( should not be that long )
BLA maybe affected little by gov shut down but he think not very drastic way.
I asked if they are thinking about check point inhibitors and their side effects , really autoimmune diseases and our Leronlimab maybe helpful to prevent those serious problems.
Dr NP said that yes , they are talking about it , it was also their observation that Leronlimab may prevent or at least minimize those severe sometime side effects of check point inhibitors ,
but for now priority is TNBC and HIV.
But they did make this observation..
And I didnt ask anything about money , sorry , when I start to talk medicine I just dont remember other things.
All together my feeling is that they believe 2019 will be very important
OUR year !!!
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
